AI Article Synopsis
- The rise of cell and gene therapies has revolutionized how we treat cancers and other diseases.
- Kymriah® (tisagenlecleucel) is a type of personalized T-cell therapy approved for specific types of blood cancers in young patients.
- The article outlines how tisagenlecleucel was developed, focusing on its effectiveness and safety.
Article Abstract
The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294746 | PMC |
| http://dx.doi.org/10.1080/21645515.2023.2210046 | DOI Listing |
Publication Analysis
Top Keywords
kymriah® tisagenlecleucel
8
overview clinical
8
clinical development
8
development journey
8
tisagenlecleucel overview
4
journey approved
4
approved car-t
4
car-t therapy
4
therapy emergence
4
emergence cell
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!